280 related articles for article (PubMed ID: 28901041)
1. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
Yoshida M; Nozawa Y; Kato D; Tabuchi H; Kuroishi K
Low Urin Tract Symptoms; 2019 Jan; 11(1):30-38. PubMed ID: 28901041
[TBL] [Abstract][Full Text] [Related]
2. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
Nozawa Y; Kato D; Tabuchi H; Kuroishi K
Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
[TBL] [Abstract][Full Text] [Related]
3. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
Kato D; Tabuchi H; Uno S
Low Urin Tract Symptoms; 2019 Jan; 11(1):14-23. PubMed ID: 28762672
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study.
Takahashi S; Kato D; Tabuchi H; Uno S
Low Urin Tract Symptoms; 2021 Jan; 13(1):79-87. PubMed ID: 32761776
[TBL] [Abstract][Full Text] [Related]
6. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
Wada N; Iuchi H; Kita M; Hashizume K; Matsumoto S; Kakizaki H
Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
[TBL] [Abstract][Full Text] [Related]
7. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
8. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.
Kato D; Tabuchi H; Uno S
Low Urin Tract Symptoms; 2019 Apr; 11(2):O152-O161. PubMed ID: 30079630
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
[TBL] [Abstract][Full Text] [Related]
10. Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β
Yamaguchi O; Ikeda Y; Ohkawa S
Low Urin Tract Symptoms; 2017 Jan; 9(1):38-45. PubMed ID: 28120446
[TBL] [Abstract][Full Text] [Related]
11. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
14. Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post-marketing study.
Katoh T; Kuwamoto K; Kato D; Kuroishi K
Int J Urol; 2016 Dec; 23(12):1009-1015. PubMed ID: 27624693
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice.
Shen YC; Wang HJ; Chuang YC
Int Urol Nephrol; 2018 Jul; 50(7):1219-1226. PubMed ID: 29882001
[TBL] [Abstract][Full Text] [Related]
16. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
[TBL] [Abstract][Full Text] [Related]
18. Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome.
Mandpe P; Prabhakar B; Shende P
Curr Drug Metab; 2020; 21(2):79-88. PubMed ID: 32334500
[TBL] [Abstract][Full Text] [Related]
19. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
20. Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study.
Shin DG; Kim HW; Yoon SJ; Song SH; Kim YH; Lee YG; Joo KJ; Bae JH; Kang TW; Jeong SJ; Woo SH; Yoo ES; Son H; Koo KC; Kim SW
Neurourol Urodyn; 2019 Jan; 38(1):295-304. PubMed ID: 30311691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
